The grant will enable the Company to buy equipment and move forward with its plans to extend its pilot scale manufacture of patches formulated with its unique TEPI Patch^® technology to GMP manufacture for clinical trials. 

The patent protected TEPI Patch technology enables the development of drug-in-adhesive patch products with better adhesion and more efficient delivery of drugs through the skin over a prolonged period. Medherant’s first product, an Ibuprofen TEPI Patch, is in Phase I clinical development with initial results expected in Q4 2018. Medherant’s business model is to develop novel best-in-class products to then out-license to established pharmaceutical companies for commercialisation.

Medherant recently installed its own pilot-scale patch manufacturing plant and has successfully produced non-GMP patches of the Ibuprofen TEPI Patch. The Company has also produced TEPI Patches for third parties interested in assessing the suitability of the TEPI technology for their drugs.